moderna news - Search News

Moderna Sales Get Lift From Early Nod

Reuters on MSN · 2d

Moderna reports surprise profit on higher-than-expected COVID vaccine sales

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.

The Boston Globe · 1d

Moderna sales get lift from early nod for newest COVID shot

Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s COVID boosters.

Wall Street Journal · 2d

Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.

FiercePharma · 2d

Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,

NBC New York · 2d

Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.

Canada, Moderna and RSV

Reuters on MSN · 1d

Canada approves Moderna's RSV vaccine for adults aged 60 and older

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorised mRNA-based shot for the condition.

Business Insider · 1d

Moderna receives Health Canada approval for RSV vaccine for 60 years, older

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease

Canada approves Moderna's RSV vaccine for those age 60 and older, company says

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorized mRNA-based shot for the condition.

23h

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

1don MSN

Moderna’s stock pops after biotech ekes out profit and revenue beats by a wide margin

Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...

BioPharma Dive2d

Moderna earnings beat forecasts, but analysts question whether sales spike will last

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

1d

Moderna EPS Beats Estimates, Sales Rise

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna Inc. stock underperforms Friday when compared to competitors

Shares of Moderna Inc. MRNA shed 6.86% to $46.83 Friday, on what proved to be an all-around favorable trading session for ...

3d

Moderna’s Bancel steps down as sales chief, keeps CEO role

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

1d

Moderna price target lowered to $111 from $125 at Barclays

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results